| Heinemann, Volker |
| Active, not recruiting | 3 | 673 | Europe | Irinotecan, Campto, Folinic Acid, Folgamma mono, 5-FU, Fluorouracil, Cetuximab, Erbitux, Bevacizumab, Avastin, Capecitabine, Xeloda, regorafenib, CAS #:755037-03-7, Irinotecan 125mg, Cetuximab wkly | Ludwig-Maximilians - University of Munich | Metastatic Colorectal Cancer | 11/23 | 12/24 | | |
| Completed | 3 | 430 | Europe | Ramucirumab, TAS 102 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH | Colorectal Cancer | 07/24 | 07/24 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Active, not recruiting | 2 | 270 | Europe | Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin | Ludwig-Maximilians - University of Munich | Metastatic Pancreatic Cancer | 07/22 | 07/23 | | |
| Active, not recruiting | 2 | 109 | Europe | Bevacizumab, Irinotecan, Folinic acid, Oxaliplatin, 5-FU, Cetuximab | Ludwig-Maximilians - University of Munich | Metastatic Colorectal Cancer | 11/23 | 12/23 | | |
NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer |
|
|
| Completed | 2 | 124 | Europe | Aflibercept + mLV5FU2, mFOLFOX7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi | Colorectal Cancer | 02/24 | 02/24 | | |
NCT04034173: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation |
|
|
| Not yet recruiting | 2 | 120 | Europe | Panitumumab, Irinotecan, Folinic acid, 5-FU | Ludwig-Maximilians - University of Munich, Amgen, ClinAssess GmbH | Treatment Related Cancer | 08/24 | 08/26 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
| Completed | 1/2 | 29 | Europe, US | MEN1611, Cetuximab | Menarini Group, Menarini Ricerche S.p.A. | Metastatic Colorectal Cancer | 01/24 | 02/24 | | |
| Recruiting | N/A | 500 | Europe, RoW | Data collection and quality of life questionnaire | Centre Leon Berard | Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation | 06/25 | 06/25 | | |
| Not yet recruiting | N/A | 130 | NA | Virtual centralized multidisciplinary tumour board | Ludwig-Maximilians - University of Munich, Charité Universitätsmedizin, Department of Hematology, Oncology and Tumor Immunology | Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication, Secondary Intervention | 03/23 | 03/25 | | |
| Stintzing, Sebastian |
| Recruiting | 2 | 35 | Europe | FOLFIRI Protocol, SCO-101 | Scandion Oncology A/S, TFS Trial Form Support | Metastatic Colorectal Cancer | 06/22 | 06/22 | | |
NCT03263663: Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model |
|
|
| Recruiting | N/A | 1000 | Europe | targeted substance according to the avatar model | PD Dr. med. Volker Heinemann, MGO Ruhr-University Bochum (RUB) | Colo-rectal Cancer, RAS Wild-type, UICC III, UICC II + RF, UICC IV Curative Intent | 01/21 | 01/25 | | |
| Active, not recruiting | N/A | 500 | Europe | Physician's choice according to patient's needs. | iOMEDICO AG | Colorectal Cancer Metastatic | 04/22 | 04/26 | | |
| Completed | N/A | 400 | Europe | FoundationOne®CDx and FoundationOne®Liquid | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG | Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer, Oesophageal Cancer, Stomach Cancer | 08/24 | 08/24 | | |
Live-RF, NCT05991102: Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With TAS-102 (Lonsurf) and Bevacizumab in Refractory Metastatic Colorectal Cancer |
|
|
| Recruiting | N/A | 12 | Europe | Radiofrequency electromagnetic field treatment, mEHT, capacitive hyperthermia, electrohyperthermia | Charite University, Berlin, Germany | Refractory Metastatic Colorectal Cancer | 11/26 | 11/26 | | |
| Giessen, Clemens |
| No trials found |
